Jenburkt Pharmaceuticals Ltd
BSE:524731
Jenburkt Pharmaceuticals Ltd
BSE:524731
Price:
785 INR
1.17%
Updated:
Jun 6, 2024
Jenburkt Pharmaceuticals Ltd
Net Income (Common)
|
Jenburkt Pharmaceuticals Ltd
Net Income (Common) Peer Comparison
Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Jenburkt Pharmaceuticals Ltd
BSE:524731
|
Net Income (Common)
₹244.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.8B
|
CAGR 3-Years
42%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹41.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹89.1B
|
CAGR 3-Years
55%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Net Income (Common)
₹38.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹15B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
See Also
What is Jenburkt Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
244.5m
INR
244.5m
INR
Based on the financial report for Dec 31, 2023, Jenburkt Pharmaceuticals Ltd's Net Income (Common) amounts to 244.5m INR.
What is Jenburkt Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
14%
14%
Over the last year, the Net Income (Common) growth was 13%. The average annual Net Income (Common) growth rates for Jenburkt Pharmaceuticals Ltd have been 12% over the past three years , 6% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
